C9 and amyotrophic lateral sclerosis: In analyzing the efficiency of the CRISPR/Cas13d treatment, we observed that a subset of C9-ALS patient cell lines, which showed relatively high efficiency in knocking down RAN translation products, exhibited a decrease in repeat-containing transcripts, whereas other cell lines with less efficient poly-dipeptide knockdown did not show a significant decrease in these transcripts.